Gold+
| Address | 100, Eulji-ro, Jung-gu, Seoul, Republic of Korea | ||
|---|---|---|---|
| Telephone | +82)2-6477-0000 | Fax | |
| Website | https://www.inno-n.com/ | ohsung.kwon1@inno-n.com | |
inno.N brings us closer to the long-awaited dreams of a healthier and more beautiful daily life by living up to its social responsibilities and rising up to the challenge. Since its establishment in 1984, inno.N has tapped into the belief that its business was also helping chart the nation’s future. This belief has served and continues to serve the company well, as it has grown into one of the leading pharmaceutical firms in the nation. Since its establishment in 1984, inno.N has gained competitiveness in the businesses of prescription drugs, active pharmaceutical ingredients, health supplements and beauty products. Drawing on the company’s experience and knowhow in developing novel drugs, inno.N succeeded in launching ‘K-CAB’, the 30th novel drug to be developed and registered in Korea, to great acclaim. Building on this success, inno.N remains committed to growing into a global bio health company built on outstanding products and technologies that bring us closer to a healthier future.
AKYNZEO® is a medicine used to prevent nausea (feeling sick) and vomiting in adults with cancer who are receiving chemotherapy (medicines to treat cancer). Some chemotherapy is known to induce severe nausea and vomiting, and AKYNZEO® is used in patients receiving either highly emetogenic (vomit-inducing) chemotherapy containing the cancer medicine cisplatin, carboplatin and AC combination(Anthracycline and Cyclophosphamide) or other chemotherapies that are moderately emetogenic. AKYNZEO® is a convenient combination therapy targeting two critical antiemetic pathways to provide long-lasting protection from CINV that is given approximately one hour before chemotherapy. As a simplified single dose formulation AKYNZEO® may also enhance patient compliance and improve adherence to guideline recommended prophylaxis.
Irinotecan HCl is the key component of chemo-treatment for colorectal cancer patients worldwide, which is supported by continuously proven survival bene t from dozens of clinical trials and clear evidences of combination therapy with molecular targeting agents. HK inno.N has been manufacturing irinotecan since 2001 and launched the 1st irinotecan product in Korea. Prescribing experiences over decade help patients and cancer care professionals to choose CALMTOP with con dence.
